We are live on
!
Find out more
Rocket Pharmaceuticals
RCKT
RCKT
186 hedge funds and large institutions have $323M invested in Rocket Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 60 increasing their positions, 71 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
72% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 18
70% more call options, than puts
Call options by funds: $325K | Put options by funds: $191K
8% more funds holding
Funds holding: 173 → 186 (+13)
3% more capital invested
Capital invested by funds: $315M → $323M (+$8.01M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.16% less ownership
Funds ownership: 89.52% → 84.36% (-5.2%)
15% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 71
Holders
186
Holders Change
+13
Holders Change %
+7.51%
% of All Funds
2.26%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
31
Increased
60
Reduced
71
Closed
18
Calls
$325K
Puts
$191K
Net Calls
+$134K
Net Calls Change
-$1.28M
Top Buyers
| 1 |
Citigroup
New York
|
+$17.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.66M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.27M |
| 4 |
BlackRock
New York
|
+$2.71M |
| 5 |
Two Sigma Investments
New York
|
+$1.79M |
Top Sellers
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
-$20.4M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$7.93M |
| 3 |
Millennium Management
New York
|
-$6.11M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.13M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$2.91M |
